中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2013年
12期
892-896
,共5页
RNA干扰%Bcl-2基因%10-羟基喜树碱%肝肿瘤%小鼠
RNA榦擾%Bcl-2基因%10-羥基喜樹堿%肝腫瘤%小鼠
RNA간우%Bcl-2기인%10-간기희수감%간종류%소서
RNA interference%Bcl-2 gene%10-hydroxycampotothecin%Liver neoplasms%Mouse
目的 探讨Bcl-2 siRNA和10-羟基喜树碱(HCPT)联合对小鼠H22肝癌移植瘤的治疗作用.方法 设计并合成针对Bcl-2 mRNA序列的siRNA,将Bcl-2 siRNA转染入小鼠H22肝癌移植瘤内并联合HCPT治疗,观察肿瘤体积和小鼠体重的变化以及小鼠的生存情况.对肿瘤组织进行石蜡切片,采用HE染色观察移植瘤组织的形态变化.采用逆转录聚合酶链反应(RT-PCR)检测移植瘤组织中Bcl-2 mRNA的表达.采用流式细胞术检测移植瘤组织中H.细胞的细胞周期和凋亡变化.结果 用药21 d后,siRNA干扰联合HCPT治疗组H22荷瘤小鼠的肿瘤体积为(571.47±67.31)mm3,明显小于HCPT治疗组[(880.47±107.31) mm3,P ＜0.05]、siRNA干扰组[(1119.55±158.60) mm3,P＜0.01]和生理盐水组[(1357.64±197.92)mm3,P＜0.01].siRNA干扰联合HCPT治疗组小鼠的生存时间为26 d,明显长于HCPT治疗组(14 d,P＜0.05)、siRNA干扰组(21 d,P＜0.05)和生理盐水组(12 d,P＜0.05).siRNA干扰联合HCPT治疗组移植瘤组织中H22细胞坏死明显,Bcl-2 mRNA表达下调,S期细胞比例减少,凋亡率升高.结论 与单一治疗组比较,Bcl-2 siRNA与HCPT联合对小鼠H22肝癌移植瘤的生长有明显的抑制作用,并可延长小鼠的生存时间.
目的 探討Bcl-2 siRNA和10-羥基喜樹堿(HCPT)聯閤對小鼠H22肝癌移植瘤的治療作用.方法 設計併閤成針對Bcl-2 mRNA序列的siRNA,將Bcl-2 siRNA轉染入小鼠H22肝癌移植瘤內併聯閤HCPT治療,觀察腫瘤體積和小鼠體重的變化以及小鼠的生存情況.對腫瘤組織進行石蠟切片,採用HE染色觀察移植瘤組織的形態變化.採用逆轉錄聚閤酶鏈反應(RT-PCR)檢測移植瘤組織中Bcl-2 mRNA的錶達.採用流式細胞術檢測移植瘤組織中H.細胞的細胞週期和凋亡變化.結果 用藥21 d後,siRNA榦擾聯閤HCPT治療組H22荷瘤小鼠的腫瘤體積為(571.47±67.31)mm3,明顯小于HCPT治療組[(880.47±107.31) mm3,P ＜0.05]、siRNA榦擾組[(1119.55±158.60) mm3,P＜0.01]和生理鹽水組[(1357.64±197.92)mm3,P＜0.01].siRNA榦擾聯閤HCPT治療組小鼠的生存時間為26 d,明顯長于HCPT治療組(14 d,P＜0.05)、siRNA榦擾組(21 d,P＜0.05)和生理鹽水組(12 d,P＜0.05).siRNA榦擾聯閤HCPT治療組移植瘤組織中H22細胞壞死明顯,Bcl-2 mRNA錶達下調,S期細胞比例減少,凋亡率升高.結論 與單一治療組比較,Bcl-2 siRNA與HCPT聯閤對小鼠H22肝癌移植瘤的生長有明顯的抑製作用,併可延長小鼠的生存時間.
목적 탐토Bcl-2 siRNA화10-간기희수감(HCPT)연합대소서H22간암이식류적치료작용.방법 설계병합성침대Bcl-2 mRNA서렬적siRNA,장Bcl-2 siRNA전염입소서H22간암이식류내병연합HCPT치료,관찰종류체적화소서체중적변화이급소서적생존정황.대종류조직진행석사절편,채용HE염색관찰이식류조직적형태변화.채용역전록취합매련반응(RT-PCR)검측이식류조직중Bcl-2 mRNA적표체.채용류식세포술검측이식류조직중H.세포적세포주기화조망변화.결과 용약21 d후,siRNA간우연합HCPT치료조H22하류소서적종류체적위(571.47±67.31)mm3,명현소우HCPT치료조[(880.47±107.31) mm3,P ＜0.05]、siRNA간우조[(1119.55±158.60) mm3,P＜0.01]화생리염수조[(1357.64±197.92)mm3,P＜0.01].siRNA간우연합HCPT치료조소서적생존시간위26 d,명현장우HCPT치료조(14 d,P＜0.05)、siRNA간우조(21 d,P＜0.05)화생리염수조(12 d,P＜0.05).siRNA간우연합HCPT치료조이식류조직중H22세포배사명현,Bcl-2 mRNA표체하조,S기세포비례감소,조망솔승고.결론 여단일치료조비교,Bcl-2 siRNA여HCPT연합대소서H22간암이식류적생장유명현적억제작용,병가연장소서적생존시간.
Objective To investigate the efficacy of treatment with siRNA targeting Bcl-2 in combination with HCPT against H22 hepatoma transplanted in mice.Methods siRNA targeting Bcl-2 mRNA was successfully designed and synthesized.Then,the Bcl-2 siRNA was transfected into H22 hepatoma transplanted in mice in combination with HCPT for treatment.The changes of tumor volume,body weight and survival rate were observed.Tumor tissues were processed into paraffin blocks and sections were stained with hematoxylin and eosin (HE) to investigate the morphological changes of the tumor cells.RT-polymerase chain reaction (PT-PCR) was used to assess the expression of Bcl-2 mRNA in tumors and cells.Cell cycle and apoptosis of H22 hepatoma cells transplanted in mice were further determined by flow cytometry.Results After treatment for 21 days,the tumor volume was around (571.47 ± 67.31)mm3 in the group of siRNA in combination with HCPT,which was significant smaller than that of the groups of HCPT [(880.47 ± 107.31)mm3,P ＜ 0.05],siRNA interfere [(1119.55 ± 158.60) mm3,P ＜ 0.01] and saline (1357.64 ± 197.92) mm3,P ＜ 0.01].The median survival time of the group receiving siRNA in combination with HCPT treatment was 26 days,which was significantly longer than that of the group receiving HCPT (14 day,P ＜ 0.05),siRNA interfere (21 day,P ＜0.05) and saline (12 day,P ＜0.05).Larger necrotic area,lower expression of Bcl-2 mRNA,less cells at S phase and more apoptotic cells could be obviously seen in tumor tissues in the group of siRNA in combination with HCPT treatment.Conclusion Bcl-2 siRNA in combination with HCPT has good synergetic antitumor efficacy in H22 hepatoma-bearing mice.
